JP2020507596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507596A5 JP2020507596A5 JP2019543851A JP2019543851A JP2020507596A5 JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5 JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- subject
- pharmaceutical composition
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216425A JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Division JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507596A JP2020507596A (ja) | 2020-03-12 |
| JP2020507596A5 true JP2020507596A5 (https=) | 2021-04-01 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (https=) |
| EP (1) | EP3582805A4 (https=) |
| JP (2) | JP2020507596A (https=) |
| KR (3) | KR20230145547A (https=) |
| CN (2) | CN110290803A (https=) |
| AU (2) | AU2018221822A1 (https=) |
| CA (1) | CA3052652A1 (https=) |
| EA (1) | EA201991870A1 (https=) |
| IL (3) | IL302777A (https=) |
| MA (1) | MA47509A (https=) |
| SG (1) | SG11201907211TA (https=) |
| WO (1) | WO2018152415A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| KR20230145547A (ko) * | 2017-02-16 | 2023-10-17 | 메디뮨 엘엘씨 | 방광암의 항-pd-l1 항체 치료 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP4153783A1 (en) * | 2020-05-21 | 2023-03-29 | Astrazeneca AB | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
| US20250388678A1 (en) * | 2024-06-25 | 2025-12-25 | Astrazeneca Ab | Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| ES2789500T5 (es) * | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| US20180364240A1 (en) * | 2015-12-10 | 2018-12-20 | Medimmune, Llc | Methods for treatment and selection of patients responsive to immune mediated cancer therapy |
| WO2017189433A1 (en) * | 2016-04-25 | 2017-11-02 | Medimmune, Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| KR20230145547A (ko) * | 2017-02-16 | 2023-10-17 | 메디뮨 엘엘씨 | 방광암의 항-pd-l1 항체 치료 |
-
2018
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507596A5 (https=) | ||
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| JP2018522850A5 (https=) | ||
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| JP2022531408A5 (https=) | ||
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2013520442A5 (https=) | ||
| CN108498532A (zh) | 骨髓抑制的治疗 | |
| JP2024038034A5 (https=) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| Lignon et al. | Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| Hyung et al. | Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| Rose et al. | A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study | |
| Fujimoto et al. | A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| Nardi et al. | FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| JP2022501332A5 (https=) | ||
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| Uranga et al. | Gastrointestinal side effects of anticancer therapy | |
| CN109073650A (zh) | 包括对西地尼布进行固定的间歇给药的方法 | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients | |
| Schieber et al. | Tarlatamab rechallenge after grade 3 cytokine release syndrome leading to tumor regression in two weeks and reopening of a collapsed lung: a case report |